United Therapeutics (NASDAQ:UTHR) CEO Sells $5,386,880.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $567.04, for a total value of $5,386,880.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,972,491.52. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ:UTHR traded down $0.19 during midday trading on Tuesday, reaching $566.80. The company’s stock had a trading volume of 402,311 shares, compared to its average volume of 477,982. The firm has a market cap of $24.06 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The business has a 50 day moving average price of $559.71 and a 200 day moving average price of $508.76.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. International Assets Investment Management LLC lifted its holdings in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on UTHR. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald boosted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. TD Cowen boosted their price target on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.